Literature DB >> 20510363

The stem cell niche in health and malignancy.

Monika L Burness1, Dorothy A Sipkins.   

Abstract

Somatic stem cells play a well-defined and important role in tissue renewal. Their malignant counterparts, cancer stem cells, are thought to be responsible for tumor initiation and possibly chemotherapy resistance, although controversy remains regarding both the origin and characterization of these cells. Both somatic and cancer stem cells appear to occupy specialized microenvironments in many organs. These niches are important for both maintenance of quiescence and control of cellular survival and proliferation. Targeting cancer stem cells and their microenvironments may provide new therapies to eradicate tumors. The efficacy of several drugs in current use is mediated at least in part via effects on the microenvironment, and new drugs that target the niche are currently in clinical trials.

Entities:  

Mesh:

Year:  2010        PMID: 20510363     DOI: 10.1016/j.semcancer.2010.05.006

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  22 in total

Review 1.  [Tumor pathophysiology].

Authors:  L A Kunz-Schughart; W Mueller-Klieser; P Vaupel
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

2.  The Effect of Bone Marrow Mesenchymal Stem Cells on Vitamin D3 Induced Monocytic Differentiation of U937 Cells.

Authors:  Zahra Molaeipour; Karim Shamsasanjan; Ali Akbari Movassaghpour; Parvin Akbarzadehlaleh; Fatemeh Sabaghi; Mahshid Saleh
Journal:  Adv Pharm Bull       Date:  2016-03-17

3.  3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?

Authors:  Pilar de la Puente; Abdel Kareem Azab
Journal:  Future Oncol       Date:  2016-03-30       Impact factor: 3.404

Review 4.  Tissue stem cells: new tools and functional diversity.

Authors:  Markus Grompe
Journal:  Cell Stem Cell       Date:  2012-06-14       Impact factor: 24.633

5.  Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma.

Authors:  Pilar de la Puente; Nancy Quan; Ryan Soo Hoo; Barbara Muz; Rebecca C Gilson; Micah Luderer; Justin King; Samuel Achilefu; Noha Nabil Salama; Ravi Vij; Abdel Kareem Azab
Journal:  Haematologica       Date:  2016-04-14       Impact factor: 9.941

6.  N-cadherin impedes proliferation of the multiple myeloma cancer stem cells.

Authors:  Nicole M Sadler; Britney R Harris; Brittany A Metzger; Julia Kirshner
Journal:  Am J Blood Res       Date:  2013-12-18

7.  Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features.

Authors:  Vilde D Haakensen; Ole Christian Lingjaerde; Torben Lüders; Margit Riis; Aleix Prat; Melissa A Troester; Marit M Holmen; Jan Ole Frantzen; Linda Romundstad; Dina Navjord; Ida K Bukholm; Tom B Johannesen; Charles M Perou; Giske Ursin; Vessela N Kristensen; Anne-Lise Børresen-Dale; Aslaug Helland
Journal:  BMC Med Genomics       Date:  2011-11-01       Impact factor: 3.063

8.  High-content image informatics of the structural nuclear protein NuMA parses trajectories for stem/progenitor cell lineages and oncogenic transformation.

Authors:  Sebastián L Vega; Er Liu; Varun Arvind; Jared Bushman; Hak-Joon Sung; Matthew L Becker; Sophie Lelièvre; Joachim Kohn; Pierre-Alexandre Vidi; Prabhas V Moghe
Journal:  Exp Cell Res       Date:  2016-12-27       Impact factor: 3.905

9.  Cancer stem cell hypothesis: a brief summary and two proposals.

Authors:  Shuhua Zheng; Longzuo Xin; Aihua Liang; Yuejun Fu
Journal:  Cytotechnology       Date:  2012-12-19       Impact factor: 2.058

10.  3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.

Authors:  Pilar de la Puente; Barbara Muz; Rebecca C Gilson; Feda Azab; Micah Luderer; Justin King; Samuel Achilefu; Ravi Vij; Abdel Kareem Azab
Journal:  Biomaterials       Date:  2015-09-12       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.